TY  - JOUR

T1  - Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data

JO  - PharmacoEconomics - Open

PY  - 2020/03/01

AU  - Bullement A

AU  - McMordie ST

AU  - Hatswell AJ

AU  - Li N

AU  - Wilson K

ED  - 

DO  - DOI: 10.1007/s41669-019-0158-8

PB  - Springer Science and Business Media LLC

VL  - 4

SP  - 133

EP  - 142

Y2  - 2024/12/22

ER  -